RayStation 9B release adds support for chemotherapy planning
RaySearch Laboratories AB (publ) announces the release of RayStation® 9B*. The latest version of its innovative treatment planning system offers several enhancements, including support for chemotherapy planning and next-level machine learning capabilities, as well as further integration with its oncology information system RayCare®*.
Support for chemotherapy is among the significant enhancements of the latest version of the treatment planning system RayStation. Other features of RayStation 9B, the second major update this year, involves deep learning segmentation using multi-modality images and machine learning capabilities enabling planning for multi-beam set plans. These enhancements enable powerful automation for even more treatment set-ups.
RayStation 9B introduces support for medical oncology with a new module for management and prescription of chemotherapy treatments. This includes tools to build a library of medical oncology regimen templates, to be used and adapted for individual patients, cycle-by-cycle approvals, and report generation for use during treatment administration. Additional tools include those for registering, activating and inactivating active substances to be used.
RayStation 9B includes real-time tracking and motion management support for TomoHelical plans (Synchrony®), as well as VSim plan approval and the ROI protect option for VMAT. Enhancements for particle therapy include support for Siemens Dual Energy CT in dose calculation, seated treatments, and full support for Hitachi proton treatment machines and Toshiba carbon ion systems. Also, the speed in Multi-Criteria Optimization for protons is significantly improved by the use of cached spot doses.
Improved support for large image datasets and further integration with RayCare, such as the possibility to run RayStation scripts from tasks in the oncology information system, is also included in the new release.
Johan Löf, founder and CEO of RaySearch, says: “With each new version of our RayStation software, we are advancing patient treatment planning with innovation and the latest in digital technology. Adding support for chemotherapy is the first application of RayStation outside of radiation therapy and it signifies important broadening of our support for comprehensive cancer care.”
About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare®*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.
About RayCare
RayCare is designed to support the complex logistical challenges of modern oncology clinics. It represents the future of oncology information system technology, supporting the vision of one oncology workflow. Many cancer patients receive a combination of treatment types, and RayCare is designed to reflect that. It will efficiently coordinate activities in radiation therapy, chemotherapy and surgery and will offer advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. RayCare is being developed with tomorrow’s requirements for advanced analytics and decision support in mind.
More information about RaySearch is available at www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
